Vallerie McLaughlin, MD
Cardiovascular Disease · Ann Arbor, MINPI 1205912268
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Merck at 55.0% of the total. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 703 payments — averaging $1347.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$521K
- Actelion Pharmaceuticals, Ltd$219K
- United Therapeutics Corporation$99K
- Actelion Pharmaceuticals US, Inc.$55K
- Bayer$22K
- Chiesi USA, Inc.$8K
- plus $24K from 9 others
Across 87 payments — averaging $6244.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$147K
- Actelion Pharmaceuticals, Ltd$123K
- United Therapeutics Corporation$106K
- Janssen Research & Development, LLC$67K
- Actelion Pharmaceuticals US, Inc.$47K
- Merck$36K
- plus $18K from 4 others
Across 1 payment — averaging $1250.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$1K
What the payments were for
- Consulting fees$471,57150%
- Speaking & faculty fees$161,18517%
- Travel & lodging$299,73532%
- Food & beverage$14,6482%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 325 | $521,031 |
| Actelion Pharmaceuticals, Ltd | 138 | $218,573 |
| United Therapeutics Corporation | 132 | $99,083 |
| Actelion Pharmaceuticals US, Inc. | 67 | $55,232 |
| Bayer | 13 | $21,931 |
| Chiesi USA, Inc. | 4 | $7,633 |
| Acceleron Pharma, Inc. | 2 | $6,777 |
| Janssen Scientific Affairs, LLC | 2 | $4,900 |
| Vectura Limited | 1 | $4,000 |
| Vertex | 3 | $3,033 |
| Regeneron | 3 | $2,703 |
| Sumitomo Pharma America, Inc. | 4 | $1,144 |
| Biomarin Pharmaceutical Inc. | 1 | $750 |
| Liquidia Technologies, Inc. | 2 | $280 |
| Sandoz | 6 | $171 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$947,240 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 519 | $12,619,089 |
| OpsumitMacitentan | 935 | $11,815,162 |
| UptraviSelexipag | 226 | $5,273,210 |
| AdempasRiociguat | 264 | $3,582,490 |
| WinrevairSotatercept-Csrk | 108 | $1,847,685 |
| Bosentan | 99 | $593,424 |
| RemodulinTreprostinil Sodium | 12 | $569,205 |
| LetairisAmbrisentan | 39 | $506,060 |
| Orenitram ErTreprostinil Diolamine | 24 | $488,747 |
| Tadalafil | 354 | $341,072 |
| RevatioSildenafil Citrate | 24 | $333,139 |
| TracleerBosentan | 25 | $297,343 |
| OpsynviMacitentan/Tadalafil | 20 | $252,896 |
| Ambrisentan | 83 | $241,814 |
| Sildenafil Citrate | 517 | $155,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan, Tracleer, Opsynvi | $55,232 | $18,232,0351,305 claims |
| BayerAdempas | $21,931 | $3,582,490264 claims |
| MerckWinrevair | $521,031 | $1,847,685108 claims |
| United Therapeutics CorporationRemodulin, Adcirca | $99,083 | $664,88037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Ann Arbor
- Marschall RungeAnn Arbor$1.8M
- Stanley ChetcutiAnn Arbor$573K
- David BachAnn Arbor$390K
- Bertram PittAnn Arbor$298K
- Victor MolesAnn Arbor$120K
- Salim HayekAnn Arbor$92K
- Ashwini KerkarAnn Arbor$84K
- Priya MehtaAnn Arbor$70K
- Raymond YeowAnn Arbor$61K
- Eric GoodAnn Arbor$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.